Revance Therapeutics Inc (NASDAQ: RVNC) stock suffered a major decline of -15.6% on 1/8/24. The shares closed at $7.05. Moreover, exceptionally high trading volume at 253% of normal accompanied the decline. The stock has declined -20.6% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
RVNC is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Revance Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Revance Therapeutics has a very low Appreciation Score of 0 and a very low Power Rating of 0, with the Lowest Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment